Human papillomavirus testing and genotyping in cervical screening

Research output: Contribution to journal › Journal article › peer-review

Standard

Human papillomavirus testing and genotyping in cervical screening. / Rebolj, Matejka; Lynge, Elsebeth; Bonde, Jesper.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 7, 2011, p. 1023-1031.

Research output: Contribution to journal › Journal article › peer-review

Harvard

Rebolj, M, Lynge, E & Bonde, J 2011, 'Human papillomavirus testing and genotyping in cervical screening', Expert Review of Anticancer Therapy, vol. 11, no. 7, pp. 1023-1031. https://doi.org/10.1586/era.11.84

APA

Rebolj, M., Lynge, E., & Bonde, J. (2011). Human papillomavirus testing and genotyping in cervical screening. Expert Review of Anticancer Therapy, 11(7), 1023-1031. https://doi.org/10.1586/era.11.84

Vancouver

Rebolj M, Lynge E, Bonde J. Human papillomavirus testing and genotyping in cervical screening. Expert Review of Anticancer Therapy. 2011;11(7):1023-1031. https://doi.org/10.1586/era.11.84

Author

Rebolj, Matejka ; Lynge, Elsebeth ; Bonde, Jesper. / Human papillomavirus testing and genotyping in cervical screening. In: Expert Review of Anticancer Therapy. 2011 ; Vol. 11, No. 7. pp. 1023-1031.

Bibtex

@article{b694d8adced74fbfab5cc67eb8fd43c1,
title = "Human papillomavirus testing and genotyping in cervical screening",
abstract = "Mass vaccination against human papillomavirus (HPV) genotypes 16 and 18 will, in the long term, reduce the incidence of cervical cancer, but screening will remain an important cancer control measure in both vaccinated and unvaccinated women. Since the 1960s, cytology screening has helped to reduce the incidence of cervical cancer, but has a low sensitivity for high-grade cervical intraepithelial neoplasia (CIN) and requires frequent testing. Several HPV tests have become available commercially. They appear to be more sensitive for high-grade CIN, and may further reduce the incidence of cervical cancer compared with cytology. However, they are associated with an increased frequency of positive tests without underlying CIN, and therefore increase the need for colposcopy and repeated testing. This problem will pose a major challenge for switching from cytology-based to HPV-based screening. The aim of this article is to discuss the role and the use of HPV tests and HPV genotyping in unvaccinated women.",
keywords = "Adult, Aged, Cervical Intraepithelial Neoplasia, Colposcopy, Female, Genotype, Humans, Mass Screening, Middle Aged, Papillomaviridae, Papillomavirus Infections, Uterine Cervical Neoplasms, Vaginal Smears, Young Adult",
author = "Matejka Rebolj and Elsebeth Lynge and Jesper Bonde",
year = "2011",
doi = "10.1586/era.11.84",
language = "English",
volume = "11",
pages = "1023--1031",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Taylor & Francis",
number = "7",

}

RIS

TY - JOUR

T1 - Human papillomavirus testing and genotyping in cervical screening

AU - Rebolj, Matejka

AU - Lynge, Elsebeth

AU - Bonde, Jesper

PY - 2011

Y1 - 2011

N2 - Mass vaccination against human papillomavirus (HPV) genotypes 16 and 18 will, in the long term, reduce the incidence of cervical cancer, but screening will remain an important cancer control measure in both vaccinated and unvaccinated women. Since the 1960s, cytology screening has helped to reduce the incidence of cervical cancer, but has a low sensitivity for high-grade cervical intraepithelial neoplasia (CIN) and requires frequent testing. Several HPV tests have become available commercially. They appear to be more sensitive for high-grade CIN, and may further reduce the incidence of cervical cancer compared with cytology. However, they are associated with an increased frequency of positive tests without underlying CIN, and therefore increase the need for colposcopy and repeated testing. This problem will pose a major challenge for switching from cytology-based to HPV-based screening. The aim of this article is to discuss the role and the use of HPV tests and HPV genotyping in unvaccinated women.

AB - Mass vaccination against human papillomavirus (HPV) genotypes 16 and 18 will, in the long term, reduce the incidence of cervical cancer, but screening will remain an important cancer control measure in both vaccinated and unvaccinated women. Since the 1960s, cytology screening has helped to reduce the incidence of cervical cancer, but has a low sensitivity for high-grade cervical intraepithelial neoplasia (CIN) and requires frequent testing. Several HPV tests have become available commercially. They appear to be more sensitive for high-grade CIN, and may further reduce the incidence of cervical cancer compared with cytology. However, they are associated with an increased frequency of positive tests without underlying CIN, and therefore increase the need for colposcopy and repeated testing. This problem will pose a major challenge for switching from cytology-based to HPV-based screening. The aim of this article is to discuss the role and the use of HPV tests and HPV genotyping in unvaccinated women.

KW - Adult

KW - Aged

KW - Cervical Intraepithelial Neoplasia

KW - Colposcopy

KW - Female

KW - Genotype

KW - Humans

KW - Mass Screening

KW - Middle Aged

KW - Papillomaviridae

KW - Papillomavirus Infections

KW - Uterine Cervical Neoplasms

KW - Vaginal Smears

KW - Young Adult

U2 - 10.1586/era.11.84

DO - 10.1586/era.11.84

M3 - Journal article

C2 - 21806326

VL - 11

SP - 1023

EP - 1031

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 7

ER -

ID: 38292913